Kamada Ltd.

Contributing Author

Recent Articles by Kamada Ltd.

Oct-19	Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026 KMDA GlobeNewswire
Oct-06	Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel KMDA GlobeNewswire
Sep-17	CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB Supply to Meet Increased Demand KMDA +5.86% GlobeNewswire
Sep-10	Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference KMDA GlobeNewswire
Sep-03	Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders KMDA GlobeNewswire
Aug-17	Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026 KMDA GlobeNewswire
Aug-12	Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance KMDA GlobeNewswire
Aug-12	Kamada Announces Planned Transition of Chief Financial Officer KMDA GlobeNewswire
Aug-05	Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026 KMDA GlobeNewswire
Jul-20	Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies KMDA GlobeNewswire
Jul-13	Kamada Highlights CYTOGAM Study Results Presented at the 2026 ISHLT Annual Meeting KMDA GlobeNewswire
Jun-01	Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory KMDA GlobeNewswire
May-13	Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year KMDA -6.76% GlobeNewswire
May-06	Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026 KMDA GlobeNewswire
Mar-31	Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders KMDA GlobeNewswire
Mar-26	Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas KMDA GlobeNewswire
Mar-11	Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth KMDA GlobeNewswire
Mar-11	Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy KMDA GlobeNewswire
Mar-04	Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026 KMDA GlobeNewswire
Jan-07	Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance KMDA +5.79% GlobeNewswire
Dec-18	Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender KMDA GlobeNewswire
Dec-08	Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026 KMDA GlobeNewswire
Nov-10	Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth KMDA +5.41% GlobeNewswire
Nov-04	Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM to Prevent Cytomegalovirus in Kidney Transplantation KMDA GlobeNewswire
Nov-03	Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025 KMDA GlobeNewswire
Oct-29	Kamada to Present at the Stifel 2025 Healthcare Conference KMDA GlobeNewswire
Sep-02	Kamada to Participate in Upcoming September Investor Conferences KMDA GlobeNewswire
Aug-13	Kamada Reports Strong Second Quarter and First Half 2025 Financial Results with 11% Year-Over-Year 6-Month Top Line Growth and a 35% Increase in Profitability; Raises Full-Year Profitability Guidance KMDA GlobeNewswire
Aug-11	Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas KMDA GlobeNewswire
Aug-06	Kamada to Announce Second Quarter and First Half Ended June 30, 2025 Financial Results on August 13, 2025 KMDA GlobeNewswire
Jun-17	Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East KMDA GlobeNewswire
May-14	Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability KMDA GlobeNewswire
May-07	Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025 KMDA GlobeNewswire
May-05	Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM KMDA GlobeNewswire

Kamada Ltd.

Recent Articles by Kamada Ltd.

Upgrade your Finviz experience